[18F]FNDP for PET Imaging of Soluble Epoxide Hydrolase (sEH)

Case ID:
Disclosure Date:
Unmet Need
Soluble epoxide hydrolase (sEH) inhibitors have been shown to effectively increase the levels of epoxyeicosatrienoic acids and reduce the levels of dihydroxyeicosatrienoic acids, which may be translated to therapeutic potentials for multiple disease indications. sEH inhibitors show great promise for the treatment of  hypertension, diabetes, stroke, dyslipidemia, pain, immunological disorders, eye diseases, neurological diseases and other indications.  sEH imaging could prove useful for drug development and patient selection strategies.

Technology Overview
The technology provides a sensitive, highly specific and easy to synthesize PET imaging agent for sEH.

Stage of Development 
Proof of concept, including PET imaging and biodistribution data, in murine and non-human primate models.

J Nucl Med. 2016 Nov; 57(11): 1817–1822  
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
[18F]FNDP for PET Imaging of Soluble Epoxide Hydrolase (sEH) PCT: Patent Cooperation Treaty United States 16/098,694 11/2/2018     Pending
For Information, Contact:
Jeanine Pennington
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum